Ocular Therapeutix
Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $325m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 150 % | 18 % | 13 % | 9 % | (14 %) | 21 % | 68 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (179 %) | (151 %) | (129 %) | (232 %) | (488 %) | (414 %) | (194 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (15 %) | (138 %) | (138 %) | (304 %) | (485 %) | (420 %) | (211 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 115 % | 104 % | 104 % | 200 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye. Its main technology is a proprietary hydrogel-based formulation that allows for sustained, localized drug delivery. This approach aims to replace the need for frequent eye drops or injections, improving patient compliance and outcomes.
The company's flagship product, DEXTENZA®, is an FDA-approved, physician-administered corticosteroid insert for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is also developing a pipeline of other product candidates for various eye conditions, including glaucoma, retinal diseases like wet age-related macular degeneration (wet AMD), and dry eye disease. Their business model revolves around leveraging this hydrogel platform to create a portfolio of products that address unmet needs in the ophthalmology market. The company generates revenue through the sale of its approved products to physicians and surgical centers.
Keywords: biopharmaceutical, ophthalmology, drug delivery, hydrogel technology, DEXTENZA, retinal diseases, glaucoma, eye care, surgical therapies, ocular inflammation